
Alnylam Moves Zilebesiran into Global Phase 3 Trial
Alnylam Advances Zilebesiran Into Global Phase 3 Cardiovascular Outcomes Trial Following Promising Phase 2 KARDIA Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized leader in RNA interference (RNAi) therapeutics, announced…












